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The EGFR inhibitors (EGFR-I) cetuximab and panitumumab and the angiogenesis inhibi-
tors (AIs) bevacizumab and aflibercept have demonstrated varying efficacy in mCRC.
Objective
To document the overall impact of specific chemotherapy regimens on the efficacy of tar-
geted agents in treating patients with mCRC. Data sources: MEDLINE, EMBASE and
Cochrane databases were searched to 2014, supplemented by hand-searching ASCO/
ESMO conference abstracts.
Study Selection
Published RCTs of patients with histologically confirmed mCRC were included if they inves-
tigated either 1) chemotherapy with or without a biological agent or 2) different chemother-
apy regimens with the same biological agent. EGFR-I trials were restricted to KRAS exon 2
wild-type (WT) populations.
Data Extraction and Synthesis
Data were independently abstracted by two authors and trial quality assessed according to
Cochrane criteria. The primary outcome was overall survival with secondary endpoints pro-
gression free survival (PFS), overall response rate (ORR) and toxicity.
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Results
EGFR-I added to irinotecan-based chemotherapy modestly improved OS with HR 0.90
(95% CI 0.81–1.00, p = 0.04), but more so PFS with HR 0.77 (95% CI 0.69–0.86,
p<0.00001). No benefit was evident for EGFR-I added to oxaliplatin-based chemotherapy
(OS HR 0.97 (95% CI 0.87–1.09) and PFS HR 0.92 (95% CI 0.83–1.02)). Significant oxali-
platin-irinotecan subgroup interactions were present for PFS with I2 = 82%, p = 0.02. Further
analyses of oxaliplatin+EGFR-I trials showed greater efficacy with infusional 5FU regimens
(PFS HR 0.82, 95% CI 0.72–0.94) compared to capecitabine (HR 1.09; 95% CI 0.91–1.30)
and bolus 5FU (HR 1.07; 95% CI 0.79–1.45); subgroup interaction was present with I2 =
72%, p = 0.03. The oxaliplatin-irinotecan interaction was not evident for infusional 5FU regi-
mens. For AIs, OS benefit was observed with both oxaliplatin-based (HR 0.83) and irinote-
can-based (HR 0.77) regimens without significant subgroup interactions. Oxaliplatin+AI
trials showed no subgroup interactions by type of FP, whilst an interaction was present for
irinotecan+AI trials although aflibercept was only used with infusional FP (I2 = 89.7%, p =
0.002).
Conclusion and Relevance
The addition of EGFR-I to irinotecan-based chemotherapy has consistent efficacy, regard-
less of FP regimen, whereas EGFR-I and oxaliplatin-based regimens were most active with
infusional 5FU. No such differential activity was observed with the varying chemotherapy
schedules when combined with AIs.
Introduction
Biologic agents have been extensively investigated in metastatic colorectal cancer (mCRC),
both in combination with chemotherapy[1–21] and as monotherapy.[22, 23] Inconsistent
results from combination therapy trials have been postulated to relate to interaction with che-
motherapy partners, both with regard epidermal growth factor receptor inhibitors (EGFR-I)
[24],[25] and anti-angiogenesis inhibitors (AIs) [26]. We undertook systematic review and
meta-analysis to evaluate the overall effect of chemotherapy partner choice when combined
with biological agents used in routine clinical care of patients with mCRC, i.e. the EGFR-I
cetuximab [2, 3, 12, 18–20, 27] and panitumumab[16, 21], as well as the AIs bevacizumab[1, 4–
9, 11, 13, 15, 17, 28] and aflibercept[14, 29]. The effect of type of FP, whether oral (capecita-
bine), infusional or bolus was also explored.
Methods
Search strategy
Publication databases (MEDLINE, EMBASE and Cochrane Trials Registry—to 31 October
2014) were searched (S1 Methods) and proceedings of major conferences (ASCO, ASCO GI,
ESMO to January 2015) were handsearched. This study was not prospectively registered with a
central registry. Unpublished data was sought from authors.
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Eligibility criteria
Published randomized controlled trials of any language or year were eligible for inclusion. Par-
ticipants included were patients with metastatic (or advanced, unresectable) colorectal cancer.
Interventions studied were EGFR-I or AIs. EGFR-I trials were restricted to KRAS exon 2
wild-type (WT) populations. Eligible comparisons were 1) chemotherapy with biological agent
versus chemotherapy alone or 2) different chemotherapy regimens with the same biological
agent.
Search results were evaluated independently by two authors (DC, NP/ES), with disagree-
ments in eligibility resolved by consensus after reference to the full text of the article. Data was
extracted into piloted forms and double-checked by another author to ensure accuracy.
Endpoints
The primary endpoint was overall survival (OS); secondary endpoints were progression free
survival (PFS), overall response rate (ORR) and toxicity. Quality of life (QoL) data was
extracted where available.
Other data extracted included PICOS, the quality/description of randomization, and any
relevant funding sources. Risk of bias was performed at the study level, using the Cochrane risk
of bias tool, with summary risk of bias as per Cochrane recommendations.
The principal summary measures were hazard ratio (HR) for OS/PFS and odds ratios for
ORR and toxicity. Meta-analysis was carried out using the generic inverse variant method,
with fixed-effects analysis and calculation of HR/OR as applicable with 95% confidence inter-
vals (CI).
Trials were characterized by type of biologic and chemotherapy backbone. The two groups
of biological therapy investigated were:
1. EGFR-I: with oxaliplatin (ox) backbone vs with irinotecan (iri) backbone.
2. AIs: with ox backbone vs with iri backbone vs FP alone.
Subgroup analysis was performed by type of FP: capecitabine, infusional or bolus. The mIFL
regimen was considered in the bolus group.
Given the increasing literature on the improved efficacy of EGFR-I in extended RAS set-
tings, we performed additional analysis for OS in trials that reported this outcome in extended
RAS wildtype populations.
Heterogeneity was explored when I2>50% and p<0.10. Sensitivity analyses and funnel plots
were undertaken to investigate possible bias.
Results
Study selection
The literature search identified 256 potentially eligible citations from 2827 search results.
Thirty-nine papers representing 23 studies comprising 10478 patients were eligible for inclu-
sion (Table 1, Fig 1). The EPIC trial [30] was excluded, as analysis by KRAS exon 2 status was
available for only 300/1298 patients, with incomplete OS and PFS data. Upon clarification with
the lead author, we confirmed that insufficient data was currently available to enable meta-
analysis and that there were no active plans for this analysis to be undertaken in the future. The
PEAK trial, comparing FOLFOX + cetuximab to FOLFOX + bevacizumab in the first-line set-
ting, was not included in quantitative analysis because it did not investigate the activity of
either cetuximab or bevacizumab alone in addition to chemotherapy but rather compared its
effects. Furthermore, both arms received the same chemotherapy backbone, meaning that it
Chemotherapy and Targeted Agents in mCRC
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Table 1. List of included trials.
Studies evaluating the addition of a biologic agent to chemotherapy (19 trials, N = 9595)
Name Author Line Experimental arm Comparator arm Number of pts Risk of
bias
Phase
EGFR Inhibitors (9 trials, N = 3492)
Oxaliplatin backbone (N = 2061)
OPUS Bokemeyer
(2009)
1st FOLFOX + Cet FOLFOX 134 L III
PRIME Douillard (2010) 1st FOLFOX + Pan FOLFOX 656 L III
COIN Maughan (2011) 1st FOLFOX/CAPOX + Cet FOLFOX/CAPOX 729 (243 FOLFOX, 472 CAPOX,




Tveit (2012) 1st FLOX + Cet, Intermittent FLOX
+ Cet
FLOX 303 L III
New EPOC Primrose (2013) 1st Perioperative FOLFOX/CAPOX
+ Cet
FOLFOX/CAPOX 182 FOLFOX, 57 CAPOX L III
Irinotecan backbone (N = 1431)
CRYSTAL Van Cutsem
(2009)
1st FOLFIRI + Cet FOLFIRI 348 L III
Study 181 Peeters (2010) 2nd FOLFIRI + Pan FOLFIRI 597 L III
PICCOLO Seymour (2013) 2nd Irinotecan + Pan Irinotecan 460 L III
New EPOC Primrose (2013) 1st Perioperative FOLFIRI + Cet FOLFIRI 26 FOLFIRI L III
Anti-VEGF agents (10 trials, n = 6103)
Oxaliplatin backbone (n = 2454)
NO16966 Saltz (2008) 1st FOLFOX/XELOX + Bev FOLFOX/XELOX 700 FOLFOX, 700 XELOX L III
E3200 Giantonio (2007) 2nd FOLFOX + Bev FOLFOX 577 L III
TML Arnold (2012) 2nd Multiple chemotherapies + Bev Multiple
Chemotherapies
477 oxali L III
ITACA Passardi (2015) 1st FOLFOX/FOLFIRI+Bev FOLFOX/FOLFIRI 221 oxali L III
Irinotecan backbone (n = 2585)
ARTIST Guan (2011) 1st mIFL + Bev mIFL 203 L III
AVF2107g Hurwitz (2004) 1st IFL + Bev IFL 813 U III
VELOUR Van Cutsem
(2012)
2nd FOLFIRI + aﬂibercept FOLFIRI 1226 L III
TML Arnold (2012) 2nd Multiple chemotherapies + Bev Multiple
chemotherapies
343 iri L III
ITACA Passardi (2015) 1st FOLFOX/FOLFIRI+Bev FOLFOX/FOLFIRI 145 iri L III
Fluoropyrimidine alone (n = 1064)
AGITG
MAX
Tebbutt (2010) 1st XB, (XB+Mitomycin C) Cape 471 L III
AVF0780g Kabbinavar
(2003)
1st FUFA + Bev 5mg/kg, FUFA
+ Bev 10mg/kg
FUFA 104 L II
AVF2192g Kabbinavar
(2005)
1st FUFA + Bev FUFA 209 L II
AVEX Cunningham
(2013)
1st XB Cape 280 L III
Studies evaluating different chemotherapy regimens added to the same biological agent (4 trials, N = 517)





1st XELIRI + Cet XELOX + Cet 89 L II
CECOG Ocvirk (2010) 1st FOLFIRI + Cet FOLFOX + Cet 62 U II
CELIM Folprecht (2010) 1st FOLFIRI + Cet FOLFOX + Cet 111 L II
(Continued)
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does not address the research question posed. The other studies comparing anti-EGFR to anti-
angiogenesis agents with the same backbone (SPIRITT, FIRE-3) are excluded for the same
reason.
The Ye study [20] (investigating the addition of cetuximab to FOLFOX/FOLFIRI) met the
set requirements, but was excluded from analysis as no results were available separately for the
FOLFOX and FOLFIRI arms. PACCE and CAIRO2 were excluded given that both arms con-
tained at least one biological agent (bevacizumab).
Risk of Bias
The overall quality of the studies was good (Table 1). Funnel plots for PFS show possible publi-
cation bias with AIs (S2 Fig).
1. The effect of chemotherapy partner on efficacy of EGFR-I. 1.1 Oxaliplatin backbone
+ EGFR-I. Five studies (COIN[12], OPUS[2], PRIME[21], NEW EPOC[27] and NORDIC VII




1st CAPIRI + Bev CAPOX + Bev 255 L II
Abbreviations: Cet—Cetuximab, Pan—Panitumumab, Bev—Bevacizumab, XB—Capecitabine + Bevacizumab, Cape—Capecitabine
doi:10.1371/journal.pone.0135599.t001
Fig 1. PRISMA flow diagram. From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMAGroup (2009).
Preferred Reporting Items for Systematic Reviews andMeta-Analysis: The PRISMA Statment. PLoS Med 6
(6): e1000097. doi:10.1371/journal.pmed1000097 For more information, visit www.prisma-statement.org.
doi:10.1371/journal.pone.0135599.g001
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chemotherapy. The addition of EGFR-I did not improve OS (HR 0.97, 95% CI 0.87–1.09,
p = 0.62, Fig 2) nor PFS (HR 0.92, 95% CI 0.83–1.02, p = 0.13, Fig 3). Overall Response Rate
(ORR) was improved by 7.5% with odds ratio (OR) 1.36 (95% CI 1.12–1.64, p = 0.002). Signifi-
cant heterogeneity was present in the PFS analysis (I2 = 69%, p = 0.006), possibly due to differ-
ences in the clinical settings and the use of different fluoropyrimidine backbone across the
studies.
1.1.1. Impact of FP type on Oxaliplatin + EGFR-I: Analysis by type of FP was performed in
the above trials. No significant interaction was present for OS (S3 Fig) but significant differ-
ences were noted for PFS (I2 = 72%, p = 0.03, Fig 4), with the infusional 5FU group demon-
strating a PFS benefit (HR 0.82 (95% CI 0.72–0.94)) in contrast to the capecitabine (HR 1.09,
95% CI 0.91–1.30) and bolus FP (HR 1.07, 95% CI 0.79–1.45) groups. Only two studies evaluat-
ing capecitabine (n = 529 patients) were included in the PFS analysis by FP, but only one study
(COIN) was included in the OS analysis, as data from the NEW EPOC Study for OS was not
available to include.
1.2 Irinotecan backbone + EGFR-I. Four trials (CRYSTAL[19], Study 181[22], PICCOLO
[16] and New EPOC [27]), involving 1431 patients, investigated the addition of EGFR-I to iri-
notecan-based chemotherapy. Addition of EGFR-I improved OS (HR 0.90, 95% CI 0.81–1.00,
p = 0.01, Fig 2) as well as PFS (HR 0.77, 95% CI 0.69–0.86, p<0.00001, Fig 3). ORR was
improved by +21.3% with OR 3.09 (95% CI 2.47–3.86, p<0.00001). Significant heterogeneity
was present in the ORR analysis (I2 = 85%, p<0.0001) but ORR was still improved in random-
effects analysis (OR 3.53, 95% CI 1.88–6.65). Analysis by FP type was not performed as trials
utilized only FOLFIRI or single agent irinotecan backbones.
1.3 Interaction between oxaliplatin and irinotecan with EGFR-I. In comparing trials
combining EGFR-I with ox to those combining EGFR-I with iri, significant interaction was
present for PFS (I2 = 71.2%, p = 0.06, Fig 2) and ORR (I2 = 96.7%, p<0.00001) but not OS (I2 =
0%, p = 0.32). When the analysis was restricted to those utilizing infusional FP regimens (i.e.
FOLFOX and FOLFIRI), interaction for PFS was no longer present (PFS I2 = 0%, p = 0.49, S4
Fig) although the ORR interaction persisted (I2 = 90.5%, p = 0.001), suggesting that choice of
FP may be responsible for the interaction between the oxaliplatin-containing v irinotecan-con-
taining regimens. To highlight this point, one can see that the pooled HR for PFS with all oxali-
platin containing regimens is 0.92 (95% CI 0.83–1.02) as compared with irinotecan containing
regimens (HR 0.77; 95% CI 0.69–0.86) (Fig 2). When only infusional 5FU regimens are consid-
ered (S4 Fig), the pooled PFS HR for oxaliplatin containing regimens is 0.82 (95% CI 0.72–
0.94) as compared with irinotecan containing regimens (HR 0.77; 95% CI 0.67–0.88). Thus
greater PFS efficacy and confidence is observed with infusional 5-FU regimens and oxaliplatin
than with bolus or capecitabine based oxaliplatin combinations.
1.4 Sensitivity analyses for EGFR-I trials—extended RAS, cetuximab/panitumumab. Of
the above trials, four trials—two using oxaliplatin (OPUS, PRIME)[31, 32] and two using irino-
tecan (CRYSTAL, Study 181)[33] have reported outcomes according to extended RAS status.
The addition of EGFR-I to oxaliplatin-based chemotherapy resulted in no significant improve-
ment to OS (HR 0.81, 95% CI 0.65–1.00, p = 0.05, Fig 5). The addition of EGFR-I to irinote-
can-based chemotherapy did improve OS (HR 0.74, 95% CI 0.63–0.89, p = 0.0009). We note,
however, that no significant subgroup differences were detected (I2 = 0%, p = 0.56).
With respect to the secondary outcome of PFS, pooled analysis was also performed. The
addition of EGFR-I to oxaliplatin-based chemotherapy improved PFS (HR 0.70, 95% CI 0.57–
0.86, p = 0.0009, S5 Fig). The addition of EGFR-I to irinotecan-based chemotherapy also
improved PFS (HR 0.64, 95% CI 0.52–0.78, p<0.00001). Again, no significant subgroup differ-
ences were detected (I2 = 0%, p = 0.52). No significant statistical heterogeneity was present for
either of the above analyses.
Chemotherapy and Targeted Agents in mCRC
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We conducted additional analyses to determine whether the choice of cetuximab or panitu-
mumab may have influenced the results of our analysis, and found that the results were not
affected. When only trials investigating cetuximab were included (4 oxaliplatin, 2 irinotecan),
addition of EGFR-I to oxaliplatin-based chemotherapy did not improve OS (HR 1.02, 95% CI
0.88–1.17, p = 0.480, S6 Fig) nor PFS (HR 0.98, 95% CI 0.87–1.11, p = 0.80, S7 Fig). Addition
of EGFR-I to irinotecan-based chemotherapy improved OS (HR 0.80, 95% CI 0.67–0.95,
Fig 2. OS outcomes for EGFR-I by chemotherapy backbone.
doi:10.1371/journal.pone.0135599.g002
Fig 3. PFS outcomes for EGFR-I by chemotherapy backbone.
doi:10.1371/journal.pone.0135599.g003
Chemotherapy and Targeted Agents in mCRC
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p = 0.01) as well as PFS (HR 0.69, 95% CI 0.56–0.86, p = 0.0007). There was again significant
subgroup interaction favouring the irinotecan-based arm with regard OS (I2 = 77.9%, p = 0.03)
and PFS (I2 = 87.3%, p = 0.005).
Repeating the analysis performed in 1.1.1 (Impact of FP type on Oxaliplatin + EGFR-I)
restricted to trials utilizing cetuximab confirmed that there was no significant subgroup inter-
action in the OS analysis. Moderate subgroup interactions were still present for PFS (I2 = 40%,
p = 0.19, S8 Fig) favouring infusional 5FU (HR 0.85, 95% CI 0.69–1.05) over bolus 5FU (HR
Fig 4. Fluoropyrimidine subgroup analysis for PFS–combining EGFR-I with oxaliplatin-based chemotherapy.
doi:10.1371/journal.pone.0135599.g004
Fig 5. OS outcomes for EGFR-I by chemotherapy backbone—extended RAS analysis.
doi:10.1371/journal.pone.0135599.g005
Chemotherapy and Targeted Agents in mCRC
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1.07, 95% CI 0.79–1.45) and capecitabine (HR 1.09, 95% CI 0.91–1.30). Given that only 4 trials
were involved overall in this analysis (OPUS, COIN, NEW EPOC, NORDIC VII), this analysis
should be interpreted with caution.
With regards panitumumab, given that there was only one oxaliplatin and two irinotecan-
based trials, meta-analysis was not performed.
2. The effect of chemotherapy partner on efficacy of anti-angiogenesis agents. 2.1 Oxa-
liplatin backbone + bevacizumab. Four trials (NO1696615, E32006, TML1 and ITACA[13])
involving 2675 patients investigated the addition of bevacizumab to oxaliplatin-based chemo-
therapy. No aflibercept trials were reported in sufficient detail for analysis. The addition of bev-
acizumab significantly improved OS (HR 0.86, 95% CI 0.79–0.94, p = 0.0005, Fig 6) and PFS
(HR 0.79, 95% CI 0.72–0.87, p<0.0001, Fig 7). ORR was improved by 4.2% with OR 1.21 (95%
CI 1.01–1.46, p = 0.04). Significant heterogeneity was present for OS (I2 = 54%), PFS (I2 =
89%) and ORR (I2 = 88%), possibly due to pooling of bevacizumab studies with differential
benefit in different lines of therapy. Random-effects modelling confirmed maintenance of OS
benefit, but PFS benefit (HR 0.76, 95% CI 0.55–1.07) and ORR benefit (OR 1.50, 95% CI 0.76–
2.97) were no longer significant.
2.1.1. Impact of FP type on oxaliplatin + bevacizumab: Analysis by type of FP was per-
formed in the NO16966 and E3200 studies. TML was excluded as separate results for the multi-
ple types of FP used (XELOX, XELIRI, FOLFOX and FOLFIRI) were not available. No
significant subgroup differences by type of FP were present. For OS, HR for the infusional
group was 0.77 (95% CI 0.65–0.90), for the capecitabine group 0.78 (95% CI 0.53–1.15) with
subgroup interaction values I2 = 0%, p = 0.93. For PFS, HR for the infusional group was 0.70
(95% CI 0.60–0.81) and for capecitabine 0.72 (95% CI 0.50–1.04) with subgroup interaction
values I2 = 0%, p = 0.387.
2.2. Irinotecan backbone + bevacizumab/aflibercept. Four bevacizumab trials (AVF2107g
[28], ARTIST[7], TML[1] and ITACA[13],) and one aflibercept study (VELOUR [29]), involv-
ing 2734 patients, investigated the addition of AIs to irinotecan-based chemotherapy. The
addition of AIs improved OS (HR 0.77, 95% CI 0.70–0.85, p<0.0001, Fig 5B) as well as PFS
(HR 0.66, 95% CI 0.60–0.73, p<0.00001, Fig 6). ORR was improved by 4.5% with OR 1.30
(95% CI 1.09–1.56, p = 0.004). Significant heterogeneity was present for PFS (I2 = 75%,
p = 0.007), ORR (I2 = 73%, p = 0.02) and toxicity (I2 = 72%, p = 0.03), likely due to differences
in the chemotherapy backbones and agents (mIFL with bevacizumab in AVF2107g and ART-
IST, FOLFIRI + aflibercept in VELOUR). Random-effects modelling confirmed maintenance
of PFS benefit but ORR benefit was no longer significant (OR 1.44, 95% CI 0.96–2.16).
2.2.1 Impact of FP type on irinotecan + bevacizumab/aflibercept: Analysis by type of FP was
performed in the AVF2107g (mIFL), ARTIST (mIFL), ITACA (FOLFIRI) and VELOUR (FOL-
FIRI) trials. As in 2.1.1, TML was excluded. For OS, the HR for the infusional group was 0.81
(95% CI 0.72–0.91) and for the bolus group 0.71 (95% CI 0.61–0.83), with subgroup interaction
values I2 = 40.4%, p = 0.20. For PFS, the HR for the infusional group was 0.76 (95% CI 0.67–
0.86) and for the bolus group 0.55 (95% CI 0.47–0.64). Although significant subgroup interac-
tion was noted between infusional and bolus 5FU groups in PFS (I2 = 90.3%, p = 0.001), we
note that the bulk of the statistical power in the infusional 5FU group (50.3% out of 58.8%
weight) was contributed to by the VELOUR study, evaluating aflibercept in the second-line
setting.
2.3. Single agent FP + bevacizumab. Two trials using infusional 5-Fluorouracil (AVF0780g
[8], AVF2192g[9]), and two using capecitabine (MAX[17], AVEX[5, 8, 9, 17]) involving 1064
patients investigated the addition of bevacizumab to single agent FP. The addition of bevacizu-
mab significantly improved OS (HR 0.81, 95% CI 0.69–0.95, p = 0.01,Fig 5C) and PFS (HR
0.55, 95% CI 0.48–0.64, p<0.00001,Fig 6). ORR was improved with pooled ORR increased by
Chemotherapy and Targeted Agents in mCRC
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10.1% (OR 1.77 (95% CI 1.28–2.46, p = 0.006)). No significant heterogeneity was present. Ana-
lysing by type of FP, no significant subgroup interactions were noted.
2.4. Interaction between oxaliplatin, irinotecan and single-agent FP with anti-angio-
genic agents. Analysing these three regimens in AI trials, significant subgroup interactions
were present with regards to PFS in favour of FP alone (I2 = 89.3%, p<0.0001, Fig 6), but no
interactions were observed in OS (I2 = 25.9%, p = 0.26, Fig 5) or ORR (I2 = 49.7%, p = 0.14).
The oxaliplatin and irinotecan groups were compared after exclusion of FP-only trials. Oxali-
platin-irinotecan subgroup interaction values were I2 = 85.5%, p = 0.009 for PFS and I2 =
62.8%, p = 0.10 for OS, suggesting greater benefit from combining irinotecan-based regimens
with VEGF inhibitors compared to oxaliplatin-based regimens. Considering infusional 5FU
trials only (i.e. bevacizumab with FOLFOX versus with FOLFIRI), the PFS interaction was no
longer present (I2 = 0%, p = 0.42).
3. Trials directly comparing different chemotherapy backbones with same targeted
agent. Four trials (CELIM, KRK0104, CECOG, Schmeigel 2013[34–36]) evaluating a total of
262 patients investigated combination of biological therapy (cetuximab in 3 studies, bevacizu-
mab in Schmeigel) with different chemotherapy backbones. Limited outcome data were avail-
able for the four studies. For the three cetuximab studies, no significant differences were
observed for OS (HR 1.20, 95% CI 0.85–1.70), PFS (meta-analysis not performed as only one
trial), or ORR (OR 1.25, 95% CI 0.64–2.45). Meta-analysis was not performed for the single
bevacizumab study, which showed no significant differences in OS or PFS between CAPOX+B
and CAPIRI+B (although it was not specifically powered for these endpoints).
Fig 6. OS outcomes for anti-angiogenic agents by chemotherapy backbone.
doi:10.1371/journal.pone.0135599.g006
Chemotherapy and Targeted Agents in mCRC
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Sensitivity analysis
We investigated the impact of excluding the NEW EPOC study, which investigated the addi-
tion of perioperative cetuximab for resectable liver metastases, as this clinical setting involving
curative attempt surgery was distinctly different to the metastatic setting of the other studies.
PFS HR was improved somewhat for oxaliplatin regimens with EGFR-I (HR 0.88, 95% CI
0.80–0.98) but unchanged for irinotecan regimens.
Similarly, we explored the exclusion of VELOUR in irinotecan-AI trials (2.2) due to the dif-
ferent mode of action of aflibercept compared to bevacizumab. Benefit was maintained for PFS
(HR 0.58, 95% CI 0.50–0.66) and OS (HR 0.73, 95% CI 0.65–0.83).
Toxicity and quality of life
The addition of biologic agents resulted in increased overall rates of toxicity (S9 and S10 Figs).
Only 7/22 trials reported quality of life outcomes using validated tools (S1 Table). The PIC-
COLO and AVF2192g studies reported improved quality of life in the experimental arm with
other trials showing no significant difference.
Considering toxicity outcomes according to chemotherapy partner, no significant subgroup
interaction was observed (I2 = 60.6%, p = 0.11) for addition of EGFR-I but less toxicity was
found adding AIs to oxaliplatin-based trials compared to irinotecan-based trials (I2 = 90.1%,
p = 0.002).
Fig 7. PFS outcomes for anti-angiogenic agents by chemotherapy backbone.
doi:10.1371/journal.pone.0135599.g007
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Discussion
Whilst biologic agents have improved outcomes for patients with mCRC and are integrated
into treatment guidelines, the issue of the optimal combination and sequencing of agents
remains unclear. This study is the first to systematically examine the effect of chemotherapy
backbone, including fluoropyrimidine choice, on the efficacy of biological treatment in mCRC.
Considering the addition of EGFR-I to chemotherapy in KRAS exon 2WT patients, benefits
in OS, PFS and ORR were found in combination with irinotecan-based but not oxaliplatin-
based chemotherapy. Investigating the EGFR-I + oxaliplatin subgroup more closely, superior
efficacy was observed in trials utilizing infusional 5FU over those using capecitabine. Subse-
quent analysis of infusional FP based trials alone demonstrated remarkably similar efficacy
between the two backbones, pointing to the use of capecitabine as a possible cause for the lower
efficacy of EGFR-I when used in combination with oxaliplatin.
This study expands on the meta-analysis by Vale et al [24] by including data from PIC-
COLO and NEW EPOC, and confirms that FP choice may be responsible for differential effi-
cacy of adding EGFR-I to ox chemotherapy. We also note the meta-analysis performed by
Loupakis et al [37] of anti-EGFR agents in the first line setting. We build upon this by including
anti-EGFR trials in all lines, trials investigating anti-angiogenesis agents and perform further
subgroup analyses. Given this consistent and independent finding, the available evidence sug-
gests that infusional 5-FU regimens combined with oxaliplatin and EGFR-I may be preferable
to bolus 5-FU or capecitabine combinations, notwithstanding other factors affecting choice of
regimen such as toxicity and patient preferences.
Two hypotheses may explain the apparent differential activity between type of FP and
EGFR-I. One explanation may be increased toxicity from capecitabine-containing regimens
with resultant decreased total dose intensity and hence efficacy. Patients in the XELOX arm of
the COIN trial received a shorter duration of treatment, median 25.1 weeks in XELOX versus
the FOLFOX arm (28.1 weeks). Diarrhoea (23% vs 16% in treatment arms), HFS (16% vs 4%)
and stomatitis (4% vs 1%) were all increased in the XELOX arm and may have led the protocol
amendment mid-study reducing the dose of capecitabine from 1000 to 850mg/m2 bid (which
also carried through to the NEW EPOC study).
Another hypothesis, albeit speculative, involves the fact that capecitabine requires metabolic
activation within cells to its active form as opposed to 5-FU. Cetuximab leads to G1 arrest and
thus decreased cell cycling might lead to less cytotoxic activity.
There is scant information as to whether capecitabine combined with irinotecan has delete-
rious effects on EGFR-I efficacy; the only trial identified investigating this combination was
KRK-0104, directly comparing CAPIRI+C and CAPOX+C (cited above) which showed no sig-
nificant differences in efficacy.
Recently, retrospective analyses of large EGFR-I trials including PRIME[32], FIRE-3[38],
CRYSTAL[33] and OPUS[31] have demonstrated restriction of treatment benefit to extended
RASWT populations (KRAS exons 2, 3 and 4 as well as NRAS exons 2, 3 and 4).
CALGB 80405[39], comparing the use of cetuximab and bevacizumab, showed no OS effi-
cacy difference in both KRAS exon 2WT and extended RASWT populations (although higher
response rate– 68.6% vs 53.6%, p<0.01 –was achieved with cetuximab in extended RASWT
populations).
The combination of the AIs bevacizumab and aflibercept with chemotherapy improved OS,
PFS and ORR with benefit preserved across both oxaliplatin- and irinotecan-based backbones.
Subgroup interaction testing favoured increased efficacy for irinotecan. This finding was
reported previously but in a pooled analysis of 3763 patients only[26]. This systematic review
confirms these findings and also includes additional trials (VELOUR and AVEX).
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Restriction to trials of AIs using infusional-only FP in combination with either ox or iri
showed a persistent significant PFS benefit but no further subgroup interaction. This interac-
tion is difficult to interpret given the VELOUR contributed to the bulk of the statistical power
in the FOLFIRI analysis. A Phase II RCT with FOLFOX+aflibercept has been incompletely
reported[14] and we were unable to include it in the analysis. Whilst there was evidence for
increased efficacy of bevacizumab added to single-agent FP compared to FP chemotherapy
alone, the lesser activity of single-agent FP means that it is usually reserved for elderly or frail
patients in routine clinical practice.
A separate question not explicitly addressed by the study is which biological agent optimally
combines with which chemotherapy agent (i.e. chemo + EGFR-I first then chemo + AI or vice
versa). Whilst FIRE-3 and PEAK point to the possibly increased efficacy of EGFR-I in RAS
WT patients, their restriction to one chemotherapy regimen (FOLFIRI in FIRE-3, FOLFOX in
PEAK) mean that they cannot definitively answer the questions posed by this paper about che-
motherapy backbone choice. We note other studies recently published that address this ques-
tion. [40]
The strengths of this study include the systematic review of all relevant trials and the rigor-
ous methodology. The large number of patients included in analysis helps draw top-level con-
clusions about the subject matter. The suggestion that FP choice may be responsible for
negative interactions between oxaliplatin-based chemotherapies and EGFR-I provides scope
for further research.
We recognize several limitations to this study, including restriction of analysis to publica-
tion-only results, statistical heterogeneity and the relatively small number of patients in direct
comparison trials.
The above meta-analysis has several implications for practice in mCRC. Assuming the avail-
ability of all agents, it would seem best to combine EGFR-I with FOLFIRI or FOLFOX based
regimens. Based on the available data, CAPOX partnered with EGFR-I appears to be the least
effective.
In contrast to the above, AIs may be combined with either oxaliplatin-based or irinotecan-
based options. The improved efficacy of AIs added to fluoropyrimidine monotherapy may
reflect their greater effectiveness in less active regimens. This points to the importance of con-
sidering use of targeted agents even in frailer patients.
Whilst this study raises interesting possibilities of an interaction between cetuximab, oxali-
platin and capecitabine, the biological basis underlying the combination of agents has not been
fully elucidated and this study points to the importance of ongoing research in this area.
Conclusions
EGFR-I are best used in combination with irinotecan based regimens or with infusional FP reg-
imens when combined with oxaliplatin. Capecitabine-oxaliplatin combinations with EGFR-I
appear less effective. No statistically significant difference in efficacy is seen when AIs are used
with both irinotecan or oxaliplatin based regimens.
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